Standing Together in Uncertain Times
Chemspec Europe returned to Cologne between 6-7 May 2026, drawing 4,238 attendees from 60 nations and 454 exhibitors from 28 countries, an increase from last year’s event.
ADVERTISEMENT
About Maren Kühr
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 276 entries already.
Entries by Maren Kühr
The European CDMO Model, Powering Biologics Innovation
Europe continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.
AI meets biotech: Europe’s new investival
Artificial intelligence is reshaping biotechnology, diagnostics and drug discovery. At the same time, Europe is competing globally for capital, talent and technological leadership. Bio:cap aims to strengthen this ecosystem by connecting investors, startups, researchers and policymakers in a new international investival in Berlin.
New CCO starts in June
Marc Clausse will take up his new role as Chief Commercial Officer at Santhera Pharmaceuticals (SIX: SANN) at the beginning of June. He succeeds Geert Jan van Daal, who is retiring.
Co-founder and CEO steps down
Dr Andrea Pfeifer, long-serving CEO and co-founder from AC Immune, has decided to retire. AC Immune’s Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.
Professor Wallhäußer Innovation Award 2026
The 2026 Professor Wallhäußer Innovation Award was presented during this year’s PharmaCongress & PharmaTechnica 2026 at the end of March. First place went to AstraZeneca for the project “Automated Reading of Agar Plates for Environmental Monitoring with AI”.
Next stage of growth with a new CEO
Dr Deborah Jones joined the Dutch Resyca BV as CEO at the beginning of April, succeeding Remko Beimers, who has stepped down from his role.
Can Europe finance and keep its biotech winners?
The recent resurgence of life sciences IPOs in the US highlights a persistent structural imbalance: Europe generates world-class science but struggles to finance and retain it. The European Life Sciences Coalition was created to address this gap by mobilizing institutional capital and strengthening the policy framework needed to scale European innovation at home.
Where Life Science Scales in Basel
The Basel region is one of the world’s leading life-science clusters. Pharmaceutical companies, biotech firms and research institutions benefit from a unique combination of talent, infrastructure and international collaboration. As the industry continues to grow, the demand for scalable laboratory and office environments within this innovation ecosystem is increasing.
Europe’s pivotal choice: Vaccination is health security
The COVID 19 pandemic demonstrated that Europe can move fast, take risk, and deliver world class vaccines when political will, science and capital are aligned. Treating vaccines as strategic assets, backed by sustained political and financial support, will be key to maintaining Europe’s long-term investment in public health and innovation.